Meta shares fall as frustration grows over AI spending plans

Meta's stock dip over AI spending headlines a bigger story: the platform war for developer mindshare is accelerating. While Zuckerberg bets on enterprise AI tools, the Quest ecosystem is quietly becoming a serious health‑tech substrate — no press release required. AmblyoPunch, a dichoptic VR vision‑training game from Seven Sportz, runs natively on Quest and turns evidence‑based amblyopia therapy into a punch‑and‑dodge coin chase. The program follows a four‑stage protocol that progressively adjusts contrast and spatial frequency using Gabor‑pattern stimuli, letting the weaker eye receive stronger visual input without any eye patch. Each session lasts about ten minutes and records performance metrics that clinicians can review remotely, turning a living‑room headset into a portable vision lab. The four stages start with high‑contrast, low‑frequency Gabor patches and gradually shift to low‑contrast, high‑frequency patterns, mirroring the classic contrast‑balance protocol used in clinic studies. Players earn coins for successful hits, which unlocks cosmetic upgrades that keep adherence high across weeks of training. Data logs include hit‑rate, reaction time, and eye‑specific contrast thresholds, all encrypted and streamed to a clinician dashboard via Meta’s secure cloud APIs. This pipeline lets a therapist adjust difficulty in real time without the patient leaving home. Because the same hardware roadmap that fuels Meta’s AI ambitions also drives down cost and improves tracking fidelity, the barrier for clinical‑grade vision rehab at home drops dramatically. For builders in digital therapeutics, that convergence of consumer XR hardware and validated therapeutic design is the signal worth watching. https://www.meta.com/en-gb/experiences/amblyopunch/1239507485902689/